Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; Temple University, Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.
Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. doi: 10.1016/j.celrep.2018.08.086.
BRCA1 functions in homologous recombination (HR) both up- and downstream of DNA end resection. However, in cells with 53BP1 gene knockout (KO), BRCA1 is dispensable for the initiation of resection, but whether BRCA1 activity is entirely redundant after end resection is unclear. Here, we found that 53bp1 KO rescued the embryonic viability of a Brca1 mouse model that harbors a stop codon in the coiled-coil domain. However, Brca1;53bp1 mice were susceptible to tumor formation, lacked Rad51 foci, and were sensitive to PARP inhibitor (PARPi) treatment, indicative of suboptimal HR. Furthermore, BRCA1 mutant cancer cell lines were dependent on truncated BRCA1 proteins that retained the ability to interact with PALB2 for 53BP1 KO induced RAD51 foci and PARPi resistance. Our data suggest that the overall efficiency of 53BP1 loss of function induced HR may be BRCA1 mutation dependent. In the setting of 53BP1 KO, hypomorphic BRCA1 proteins are active downstream of end resection, promoting RAD51 loading and PARPi resistance.
BRCA1 在 DNA 末端切除的上下游都参与同源重组 (HR)。然而,在 53BP1 基因敲除 (KO) 的细胞中,BRCA1 对于起始切除并不必需,但末端切除后 BRCA1 的活性是否完全冗余尚不清楚。在这里,我们发现 53bp1 KO 挽救了带有卷曲螺旋结构域终止密码子的 Brca1 小鼠模型的胚胎活力。然而,Brca1;53bp1 小鼠易发生肿瘤形成,缺乏 Rad51 焦点,对 PARP 抑制剂 (PARPi) 治疗敏感,表明 HR 功能不足。此外,BRCA1 突变型癌细胞系依赖于保留与 PALB2 相互作用能力的截断 BRCA1 蛋白,以形成 53BP1 KO 诱导的 RAD51 焦点和 PARPi 耐药性。我们的数据表明,53BP1 功能丧失诱导的 HR 的整体效率可能依赖于 BRCA1 突变。在 53BP1 KO 的情况下,低功能的 BRCA1 蛋白在末端切除后下游活跃,促进 RAD51 加载和 PARPi 耐药性。